Printer Friendly

MEDTRONIC RELEASES FIRST COMPLETE TRANSVENOUS TIERED-THERAPY SYSTEM FOR TREATMENT OF TACHYARRHYTHMIA

 MINNEAPOLIS, Dec. 9 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) had cleared for commercial marketing the Transvene(TM) lead system for use with the implantable Medtronic PCD(R) device. Medtronic Transvene leads and the PCD comprise the first complete transvenous, tiered therapy system to be approved by the FDA in the United States.
 William W. George, Medtronic president and chief executive officer, noted that, by reducing surgical and hospitalization costs, the Transvene system "offers substantial economies while providing patient- friendly therapy and the highest degree of technological sophistication now available in an implantable therapeutic device." Earlier device and lead combinations cleared by the FDA either require opening the chest for implant or do not offer the tiered therapy of the PCD.
 Maneuvered through the vascular system, Transvene leads deliver the PCD's full range of automatically administered therapies for controlling potentially life-threatening occurrences of ventricular arrhythmias in which the heart beats too fast.
 During clinical evaluation, patients with Transvene lead systems experienced 99.5 percent survival from sudden cardiac death during the first year. In addition, the PCD Transvene system terminated more than 90 percent of episodes of ventricular tachycardia with imperceptible electrical impulses in the pacing range that made higher-intensity impulses unnecessary.
 Implantable cardioverter-defibrillator systems are especially attractive in the world's increasingly cost-conscious health care environment because they treat potentially life-threatening episodes outside a hospital setting. Additionally, the PCD Transvene system affords a simpler implant procedure that reduces costs related to surgery and recovery. Hospitalization time at implant is typically reduced from 10 days to 7 days when the system incorporates the new Transvene leads instead of epicardial leads.
 During clinical evaluation of the Transvene system, patient mortality resulting from surgery showed a significant decrease as compared with the rate for patients receiving epicardial leads. The rate for Transvene patients was 0.7 percent compared with 5.3 percent for epicardial lead patients.
 Medtronic, Inc., headquartered in Minneapolis, is the world's leading therapeutic medical device company.
 -0- 12/9/93
 /CONTACT: Dale Beumer, investor relations, 612-574-3038; or Dick Reid, public relations, 612-574-3052, both of Medtronic/
 (MDT)


CO: Medtronic, Inc. ST: Minnesota IN: HEA SU: PDT

CP-AL -- MN012 -- 2337 12/09/93 16:13 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1993
Words:373
Previous Article:NEW $99 DISNEYLAND ANNUAL PASSPORT OFFERS UNPRECEDENTED BARGAIN ON YEAR-ROUND ADMISSION
Next Article:COMPUTER PETROLEUM CORP. REPORTS THIRD QUARTER RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters